Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.
复制标题
抗病毒单克隆抗体作为COVID-19治疗的挑战和机遇
DOI：
10.1016/j.addr.2020.12.004
复制
发表时间：
2021-03
影响因子：
16.1
通讯作者：
Lai SK
中科院分区：
文献类型：
--
作者：
Cruz-Teran C;Tiruthani K;McSweeney M;Ma A;Pickles R;Lai SK
为应对COVID-19大流行，全球开展了前所未有的努力，以推进针对SARS-CoV-2的强效中和单克隆抗体作为治疗方法。然而，历史上推进抗病毒单克隆抗体（mab）治疗其他呼吸道感染的努力在临床中遭遇了明显的失败。通过研究SARS-CoV-2和类似病毒在肺内传播的机制，以及系统注射单抗的现有生物分布数据，我们强调了目前针对COVID-19的抗病毒单抗面临的挑战。我们总结了目前正在开发的一些领先的单克隆抗体，并提出了支持吸入抗病毒单克隆抗体作为COVID-19早期干预措施的证据，可以预防与感染相关的重要肺部疾病。
To address the COVID-19 pandemic, there has been an unprecedented global effort to advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical efforts to advance antiviral monoclonal antibodies (mAbs) for the treatment of other respiratory infections have been met with categorical failures in the clinic. By investigating the mechanism by which SARS-CoV-2 and similar viruses spread within the lung, along with available biodistribution data for systemically injected mAb, we highlight the challenges faced by current antiviral mAbs for COVID-19. We summarize some of the leading mAbs currently in development, and present the evidence supporting inhaled delivery of antiviral mAb as an early intervention against COVID-19 that could prevent important pulmonary morbidities associated with the infection.
登录
查看更多内容
影响因子：
56.9
作者：
Cai, Yongfei;Zhang, Jun;Chen, Bing
通讯作者：
Chen, Bing
DOI：
10.1073/pnas.2434327100
发表时间：
2003-12-09
影响因子：
11.1
作者：
Brock, SC;Goldenring, JR;Crowe, JE
通讯作者：
Crowe, JE
影响因子：
4.8
作者：
Byrnes, James R.;Zhou, Xin X.;Wells, James A.
通讯作者：
Wells, James A.
影响因子：
5.4
作者：
Barman, S;Adhikary, L;Nayak, DP
通讯作者：
Nayak, DP
影响因子：
11.1
作者：
Burgess, Gary;Boyce, Malcolm;Palframan, Roger
通讯作者：
Palframan, Roger